Compare Enbridge Inc (ENB) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Inovio Pharmaceuticals Inc — how do they compare? Enbridge Inc trades at $56.23 (market cap $121.39B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $96.26M). The key difference: Enbridge Inc is far larger — about 1261.1× Inovio Pharmaceuticals Inc's market cap, and Enbridge Inc pays a 5.01% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ENB | INO | |
|---|---|---|
Market Cap | $121.39B | $96.26M |
Sector | Energy | Health |
52-Week High | $58.04 | $2.87 |
52-Week Low | $44.59 | $1.05 |
Enterprise Value | $202.19B | $67.27M |
Dividend Yield | 5.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $56.20, up 0.55% with a bullish technical outlook. Recent earnings show mixed results with Q1 2026 beating estimates but Q3 2025 missing. The company maintains strong cash flow from operations of $12.27B in 2025 and a 5.1% dividend yield. Revenue grew to $65.19B in 2025, with net income margin at 10%. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains positive due to $28B in growth projects and stable dividends, but risks include high debt levels (debt-to-asset ratio 48.81% in 2025) and sensitivity to energy market volatility. The stock offers income appeal but faces execution risks on capital expenditures.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
